GD2directed
GD2directed therapies refer to treatments that recognize and bind to GD2, a disialoganglioside abundantly expressed on many neuroectodermal tumors, most notably neuroblastoma, as well as some melanomas and sarcomas. GD2 is present at lower levels in certain normal tissues, particularly peripheral nerves, making it a useful but challenging target for immunotherapy due to potential neuropathic pain and other toxicities.
The most developed GD2-directed modalities are monoclonal antibodies. These antibodies bind GD2 on tumor cells and
Safety considerations for GD2-directed therapies include neuropathic pain arising from GD2 expression on nerve fibers, fever,
Regulatory and research status varies by country. Several GD2-directed antibodies have approvals in some regions for
GD2-directed immunotherapy remains an active area of cancer research, offering a framework for targeting glycolipid antigens